Cargando…

Is Hypoxia a Factor Influencing PSMA-Directed Radioligand Therapy?—An In Silico Study on the Role of Chronic Hypoxia in Prostate Cancer

SIMPLE SUMMARY: Tumor hypoxia is considered a critical factor associated with the resistance of conventional radiotherapy, where the X-ray-induced free radicals lead to DNA damage in a manner that is strongly dependent on the tissue oxygenation. The emerging PSMA-directed radioligand therapy (RLT) e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Birindelli, Gabriele, Drobnjakovic, Milos, Morath, Volker, Steiger, Katja, D’Alessandria, Calogero, Gourni, Eleni, Afshar-Oromieh, Ali, Weber, Wolfgang, Rominger, Axel, Eiber, Matthias, Shi, Kuangyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307065/ https://www.ncbi.nlm.nih.gov/pubmed/34298642 http://dx.doi.org/10.3390/cancers13143429

Ejemplares similares

Metal-Based PSMA Radioligands
por: Gourni, Eleni, et al.
Publicado: (2017)

Combined [68 Ga]Ga-PSMA-11 and low-dose 2-[18F]FDG PET/CT using a long-axial field of view scanner for patients referred for [177Lu]-PSMA-radioligand therapy
por: Alberts, Ian, et al.
Publicado: (2022)

Lu-177-PSMA dosimetry for kidneys and tumors based on SPECT images at two imaging time points
por: Chen, Gefei, et al.
Publicado: (2023)

Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with (177)Lu-PSMA I&T therapy
por: Xue, Song, et al.
Publicado: (2022)

A randomised, prospective and head-to-head comparison of [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007 for the detection of recurrent prostate cancer in PSMA-ligand PET/CT—Protocol design and rationale
por: Alberts, Ian, et al.
Publicado: (2022)

Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with (131)I-MIP-1095
por: Afshar-Oromieh, Ali, et al.
Publicado: (2017)

Preclinical biodistribution and dosimetry and human biodistribution comparing (18)F-rhPSMA-7 and single isomer (18)F-rhPSMA-7.3
por: Knorr, Karina, et al.
Publicado: (2022)

Assessment of malignancy and PSMA expression of uncertain bone foci in [(18)F]PSMA-1007 PET/CT for prostate cancer—a single-centre experience of PET-guided biopsies
por: Vollnberg, Bernd, et al.
Publicado: (2022)

New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress
por: Imlimthan, Surachet, et al.
Publicado: (2021)

Diagnostic accuracy of [(18)F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer
por: Mingels, Clemens, et al.
Publicado: (2022)

Radiolabeled PSMA Inhibitors
por: Neels, Oliver C., et al.
Publicado: (2021)

Pharmacological Optimization of PSMA-Based Radioligand Therapy
por: van der Gaag, Suzanne, et al.
Publicado: (2022)

Comparing the clinical performance and cost efficacy of [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007 in the diagnosis of recurrent prostate cancer: a Markov chain decision analysis
por: Alberts, Ian, et al.
Publicado: (2021)

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
por: Jones, Wallace, et al.
Publicado: (2020)

Effect of the versatile bifunctional chelator AAZTA(5) on the radiometal labelling properties and the in vitro performance of a gastrin releasing peptide receptor antagonist
por: Hofstetter, Michael, et al.
Publicado: (2020)

PSMA Theranostics: Current Status and Future Directions
por: Rahbar, Kambiz, et al.
Publicado: (2018)

Synthesis and Preclinical Evaluation of (177)Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer
por: Wurzer, Alexander, et al.
Publicado: (2022)

(R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors
por: Gourni, Eleni, et al.
Publicado: (2015)

Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands
por: Lundmark, Fanny, et al.
Publicado: (2022)

Long-axial field-of-view PET/CT: perspectives and review of a revolutionary development in nuclear medicine based on clinical experience in over 7000 patients
por: Alberts, Ian, et al.
Publicado: (2023)

Joint EANM/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT)
por: Kratochwil, Clemens, et al.
Publicado: (2023)

EARL compliance measurements on the biograph vision Quadra PET/CT system with a long axial field of view
por: Prenosil, George A., et al.
Publicado: (2022)

Large language models (LLM) and ChatGPT: what will the impact on nuclear medicine be?
por: Alberts, Ian L., et al.
Publicado: (2023)

The influence of digital PET/CT on diagnostic certainty and interrater reliability in [(68)Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer
por: Alberts, Ian, et al.
Publicado: (2021)

Galectin-3: The Impact on the Clinical Management of Patients with Thyroid Nodules and Future Perspectives
por: Bartolazzi, Armando, et al.
Publicado: (2018)

Performance of [(68)Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy—a multi-centre evaluation of 2533 patients
por: Afshar-Oromieh, Ali, et al.
Publicado: (2021)

Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving (177)Lu-PSMA-617 Radioligand Therapy
por: Seifert, Robert, et al.
Publicado: (2020)

Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer
por: Wang, Hui, et al.
Publicado: (2023)

Feasibility of late acquisition [68Ga]Ga-PSMA-11 PET/CT using a long axial field-of-view PET/CT scanner for the diagnosis of recurrent prostate cancer—first clinical experiences
por: Alberts, Ian, et al.
Publicado: (2021)

Adoption of Lutetium-(177) PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020
por: Flegar, Luka, et al.
Publicado: (2023)

(177)Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer
por: von Eyben, Finn Edler, et al.
Publicado: (2019)

Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile
por: Deberle, Luisa M., et al.
Publicado: (2020)

Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity
por: Deberle, Luisa M., et al.
Publicado: (2020)

Factors Influencing the Therapeutic Efficacy of the PSMA Targeting Radioligand (212)Pb-NG001
por: Stenberg, Vilde Yuli, et al.
Publicado: (2022)

PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor?
por: Rizzo, Alessio, et al.
Publicado: (2022)

Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials
por: Jang, Albert, et al.
Publicado: (2023)

Correction to: Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis
por: Alberts, Ian Leigh, et al.
Publicado: (2021)

Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis
por: Alberts, Ian Leigh, et al.
Publicado: (2021)

Artificial intelligence for reducing the radiation burden of medical imaging for the diagnosis of coronavirus disease
por: Hu, Jiaxi, et al.
Publicado: (2023)

Streamlined Schemes for Dosimetry of (177)Lu-Labeled PSMA Targeting Radioligands in Therapy of Prostate Cancer
por: Kurth, Jens, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_05fo79mn6h509kub9j9c2ohnvt